Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report released on Thursday morning. The firm issued a hold rating on the medical research company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research report on Monday, November 11th.

Cytosorbents Stock Up 1.2 %

Shares of NASDAQ:CTSO opened at $0.89 on Thursday. The company’s 50-day moving average is $0.98 and its 200 day moving average is $1.01. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $2.15.

Institutional Investors Weigh In On Cytosorbents

Institutional investors have recently added to or reduced their stakes in the business. CM Management LLC boosted its position in Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after purchasing an additional 25,000 shares during the period. Sargent Investment Group LLC lifted its stake in shares of Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after buying an additional 67,181 shares in the last quarter. Atomi Financial Group Inc. bought a new position in Cytosorbents in the 3rd quarter worth approximately $51,000. Finally, Geode Capital Management LLC lifted its position in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after acquiring an additional 32,415 shares in the last quarter. 32.87% of the stock is owned by hedge funds and other institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.